New research suggests a genomic test may provide detailed information on how well a transplanted heart is performing. The gene expression profiling (GEP) test, known as the Allomap® test, is currently used to detect the absence of heart transplant rejection instead of routine invasive heart muscle biopsies, but has now been shown to correlate with oxygen saturation levels, the pressure in the heart before pumping, and the electrical properties of the transplanted heart. These measures are crucial to understanding how well the transplanted heart is functioning.
The research will be presented on Tues., March 27, at the American College of Cardiology’s 56th Annual Scientific Session in New Orleans by Martin Cadeiras, M.D., postdoctoral research fellow in the lab of Mario Deng, M.D., director of cardiac transplantation research and associate professor of clinical medicine at Columbia University College of Physicians and Surgeons, and cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center. The presentation is based on preliminary data on 80 patients who received the GEP test. Physicians hope to confirm these results in future studies.
"Understanding how the GEP score differentiates heart transplant function may provide a valuable tool to help tailor therapies to meet the specific needs of each heart transplant patient," said Dr. Deng.
Until recently, following a heart transplant, patients had to go through invasive heart-muscle biopsies to check for organ rejection. The GEP test is a non-invasive alternative that provides a molecular score measuring the body’s immune response to the heart transplant. A below-threshold test score identifies transplant patients who are at very low risk for rejecting their transplanted hearts and who can be monitored and managed using noninvasive methods such as the GEP test. Those patients may benefit from being more aggressively weaned off intensive immunosuppressive regimens. This new research suggests that the use of this test may have much greater potential than simply identifying patients without rejection.
Approximately 30 percent of all heart transplant patients reject their new heart at least once in the first year after transplantation. Transplant patients are then treated with anti-rejection medications, which increase the potential for medication side effects.
The GEP test is covered by Medicare and is available to heart transplant patients, ages 15 and older, after two months post-transplantation.
Source: Columbia University Medical Center
Related stories:
Embryonic stem cells might help reduce transplantation rejection
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
Disclosure of organ transplant risks: A question of when, not if
University of Pennsylvania School of Medicine physicians and bioethicists are calling for a new, more standardized way for patients in need of organ transplants to be informed of the risks they face. If adopted, their policy recommendations could promote greater equity in how organs are allocated while restricting patients' abilities to "cherry-pick" the best organs.
Caution on stem cell therapy
A single organ may contain more than one type of adult stem cell – a discovery that complicates prospects for using the versatile cells to replace damaged tissue as a treatment for disease, according to a new study from the laboratory of geneticist Mario Capecchi, the University of Utah's Nobel Laureate.
Medics solve an ancient riddle -- and offer new tool for diagnosis
A puzzling medical condition, identified more than 2,000 years ago by Hippocrates, has finally been explained by researchers at the University of Leeds.
Important Plant Enzymes Identified
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have identified enzymes important in the modification of isoflavonoids, natural plant products that help plants resist fungal infections, and may have beneficial health effects for humans as well. The research, which will be published online May 22, 2008, in
The Plant Journal, may pave the way for implanting the isoflavonoid-synthesis pathway into bioenergy crops to promote disease resistance and thereby prevent yield losses, and/or to enhance the production of other useful chemical feedstocks.
Studies test new approaches to islet transplantation
Researchers from 11 medical centers in the United States, Canada, Sweden, and Norway have begun testing new approaches to transplanting clusters of insulin-producing islets in adults with difficult-to-control type 1 diabetes. The clinical studies, funded by the National Institutes of Health (NIH), will determine whether changes to current methods of islet transplantation lead to improved, long-lasting control of blood glucose with fewer side effects.
New system for classifying infant lung disease developed
A new classification system of rare lung diseases in infants is improving diagnosis and treatment. The system clears up considerable confusion about how to classify and treat diseases that are rarely seen by most doctors and pathologists, says Gail H. Deutsch, M.D., lead author of the multi-center study that developed the new guidelines.